Novartis Historical Financial Ratios
NVS Stock | USD 110.38 0.71 0.64% |
Novartis is lately reporting on over 102 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 80.85 will help investors to properly organize and evaluate Novartis AG ADR financial condition quickly.
Novartis |
About Novartis Financial Ratios Analysis
Novartis AG ADRFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Novartis investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Novartis financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Novartis history.
Novartis Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Novartis AG ADR stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Novartis sales, a figure that is much harder to manipulate than other Novartis AG ADR multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is Novartis AG ADR dividend as a percentage of Novartis stock price. Novartis AG ADR dividend yield is a measure of Novartis stock productivity, which can be interpreted as interest rate earned on an Novartis investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Most ratios from Novartis' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Novartis AG ADR current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. At this time, Novartis' Interest Coverage is comparatively stable compared to the past year. Capex To Operating Cash Flow is likely to gain to 0.24 in 2025, whereas Dividend Yield is likely to drop 0.02 in 2025.
2022 | 2023 | 2025 (projected) | Dividend Yield | 0.0381 | 0.0344 | 0.0247 | Price To Sales Ratio | 3.8 | 4.52 | 2.76 |
Novartis fundamentals Correlations
Click cells to compare fundamentals
Novartis Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Novartis fundamentals Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Price To Sales Ratio | 4.47 | 4.31 | 3.73 | 3.8 | 4.52 | 2.76 | |
Dividend Yield | 0.0325 | 0.0373 | 0.0381 | 0.0344 | 0.0388 | 0.0247 | |
Ptb Ratio | 3.8 | 2.92 | 3.32 | 4.52 | 4.46 | 2.35 | |
Days Sales Outstanding | 73.41 | 57.18 | 69.68 | 73.34 | 67.32 | 80.85 | |
Book Value Per Share | 24.89 | 30.24 | 27.24 | 22.37 | 21.93 | 17.82 | |
Free Cash Flow Yield | 0.0514 | 0.0613 | 0.0587 | 0.0555 | 0.0703 | 0.048 | |
Operating Cash Flow Per Share | 5.99 | 6.72 | 6.53 | 6.92 | 8.76 | 9.19 | |
Stock Based Compensation To Revenue | 0.0156 | 0.0148 | 0.0132 | 0.0185 | 0.0202 | 0.0115 | |
Pb Ratio | 3.8 | 2.92 | 3.32 | 4.52 | 4.46 | 2.35 | |
Ev To Sales | 4.88 | 4.09 | 4.2 | 4.8 | 4.18 | 2.92 | |
Free Cash Flow Per Share | 4.86 | 5.4 | 5.3 | 5.6 | 6.86 | 7.2 | |
Roic | 0.0746 | 0.0761 | 0.23 | 0.0805 | 0.11 | 0.16 | |
Inventory Turnover | 2.12 | 2.38 | 2.16 | 2.11 | 2.24 | 1.82 | |
Net Income Per Share | 3.55 | 10.71 | 3.19 | 7.11 | 5.93 | 3.06 | |
Days Of Inventory On Hand | 172.13 | 153.34 | 169.11 | 173.05 | 162.85 | 184.43 | |
Payables Turnover | 2.8 | 2.86 | 3.01 | 2.53 | 2.81 | 3.98 | |
Capex To Revenue | 0.0518 | 0.0562 | 0.0515 | 0.059 | 0.0737 | 0.0446 | |
Cash Per Share | 5.08 | 12.63 | 8.68 | 6.68 | 6.64 | 4.09 | |
Pocfratio | 15.76 | 13.09 | 13.85 | 14.59 | 11.15 | 15.29 | |
Interest Coverage | 11.68 | 33.23 | 10.99 | 11.43 | 14.46 | 20.44 | |
Payout Ratio | 0.87 | 0.31 | 1.08 | 0.49 | 0.64 | 0.42 | |
Pfcf Ratio | 19.44 | 16.31 | 17.05 | 18.02 | 14.23 | 19.76 | |
Days Payables Outstanding | 130.42 | 127.74 | 121.29 | 144.16 | 130.1 | 84.9 | |
Ev To Operating Cash Flow | 17.84 | 14.33 | 15.29 | 15.49 | 12.28 | 16.14 | |
Pe Ratio | 26.65 | 8.22 | 28.35 | 14.2 | 16.46 | 14.26 | |
Ev To Free Cash Flow | 22.01 | 17.85 | 18.82 | 19.13 | 15.67 | 20.85 | |
Earnings Yield | 0.0375 | 0.12 | 0.0353 | 0.0704 | 0.0608 | 0.0502 | |
Net Debt To E B I T D A | 0.93 | 1.17 | 1.65 | 0.6 | 1.39 | 0.5 | |
Tangible Book Value Per Share | (4.45) | 1.8 | (0.7) | 0.89 | (3.75) | (3.56) | |
Receivables Turnover | 4.97 | 6.38 | 5.24 | 4.98 | 5.42 | 5.53 | |
Graham Number | 44.53 | 85.27 | 44.18 | 59.75 | 54.07 | 34.32 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Novartis Stock Analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.